(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pedal Power: Divulging Well known Bike Brands for Each Cyclist - 2Inside Plan with Houseplants: An Aide
- 3Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- 4Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- 5The Best Internet Mastering Stages for Expertise Improvement
- Executed Iranian nuclear scientist confessed to aiding Israel after torture, threats against mother
- Brazil's Bolsonaro to continue his sentence at home because of poor health
- Creativity Revealed: A Survey of \Making Shocking Looks\ Cosmetics Item
- These Are the Journalists Israel Has Killed Since the Start of the Iran War
- Instructions to Clean and Really focus on Your Lab Precious stone
- Scientists are getting our robotic explorers ready to help send humans to Mars
- Current Chateaus: Advancement and Style
- 21 Things You Ought to Never Tell Your Childless Companion
- Chinese construction workers in Israel: 'I’d rather be bombed than live in poverty'
